SITC CPG Webinar - Immune Checkpoint Inhibitor-related Adverse Events: CE Information

Joint Accreditation Statement

thumbnail image
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2893-L01-P.

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses. 

Hardware/Software Requirements
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Educational Objectives

Upon completion of this program, participants will be able to:

  • Select appropriate diagnostics and biomarker testing for a patient being considered for immunotherapy based on the expert panel recommendations in the CPG
  • Implement immunotherapy treatments effectively and appropriately according to the recommendations in the SITC CPG
  • Appraise patterns of response to immunotherapy in order to appropriately monitor and manage patients during treatment
  • Identify signs and symptoms of common immunotherapy-related toxicities and implement appropriate management strategies based on the EP recommendations
  • Describe considerations and available tools to assess and support patient quality of life during immunotherapy treatment

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
Postgraduate Institute for Medicine SITC Logo

This webinar is supported, in part, by independent medical education grants from
Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.